SABA ILAC SANAYI
GenericsSABA ILAC SANAYI is a generic drug manufacturer focused on Respiratory.
SABA ILAC SANAYI's Key Drugs
SABA ILAC SANAYI's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SABA ILAC SANAYI's Recent FDA Approvals
New NDA/BLA approvals for SABA ILAC SANAYI over the last two years — novel drugs only, excluding generics and label supplements.
SABA ILAC SANAYI's Therapeutic Areas
SABA ILAC SANAYI's approved drugs and pipeline span 1 therapeutic area, led by Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SABA ILAC SANAYI's Top Competitors
SABA ILAC SANAYI's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SABA ILAC SANAYI Pipeline Snapshot
Active clinical trials for SABA ILAC SANAYI across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2025-04-25
- Latest
- 2025-04-25
- Applications
- 1